D.E. Shaw & Co’s Faeth Therapeutics FTH Stock Holding History

D.E. Shaw & Co’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-645	Closed	-$29K	–	5502
2022 Q2	$29K	Buy	+645	New	+$24.2K	﹤0.01%	4937

Other funds holding FTH

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co's FTH Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Faeth Therapeutics (FTH) in Q3 2022, closing a stake of 645 shares — an estimated $29K sold.

D.E. Shaw & Co first reported a position in FTH in Q2 2022 and held it in 1 quarter. The position peaked at $29K in Q2 2022. 30 funds tracked by Wall St. Rank hold FTH as of Q3 2022.

D.E. Shaw & Co reported no remaining Faeth Therapeutics position as of Q3 2022 after selling out during the quarter.
D.E. Shaw & Co sold 645 Faeth Therapeutics shares in Q3 2022, an estimated $29K.
D.E. Shaw & Co first reported a position in Faeth Therapeutics in Q2 2022 and held it in 1 quarter.
D.E. Shaw & Co's Faeth Therapeutics position peaked at $29K in Q2 2022.
30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.